Therapeutic targeting of oncogenic tyrosine phosphatases

Cancer Research

Volumn 77, Issue 21, 2017, Pages 5701-5705

  Frankson, Rochelle ^a   Yu, Zhi Hong ^a   Bai, Yunpeng ^a   Li, Qinglin ^a   Zhang, Ruo Yu ^a   Zhang, Zhong Yin ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CMPD 43; GS 493; IIB 08; PHOSPHATASES OF REGENERATING LIVER; PROTEIN INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; PYRIDONE DERIVATIVE; SHP 099; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; GLIOBLASTOMA; HUMAN; IC50; MALIGNANT NEOPLASM; MELANOMA; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOGENESIS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASM; ONCOGENE; PROCEDURES; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENESIS; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; ONCOGENES; PROTEIN TYROSINE PHOSPHATASES; SIGNAL TRANSDUCTION;

EID: 85035008860     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-17-1510     Document Type: Review

References (43)

1. Julien SG, Dube N, Hardy S, Tremblay ML. Inside the human cancer tyrosine phosphatome. Nat Rev Cancer 2011;11:35–49.
2. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE. Crystal structure of the tyrosine phosphatase SHP-2. Cell 1998;92:441–50.
3. Chan G, Neel BG. Role of PTPN11 (SHP2) in cancer. In: Neel BGand-Tonks NK, editors. Protein tyrosine phosphatases in cancer. New York: Springer ScienceþBusiness Media; 2016. pp.115–43.
4. Huang WQ, Lin Q, Zhuang X, Cai LL, Ruan RS, Lu ZX, et al. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis. Curr Cancer Drug Targets 2014;14:567–88.
5. Bunda S, Burrell K, Heir P, Zeng L, Alamsahebpour A, Kano Y, et al. Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. Nat Commun 2015;6:8859.
6. Chan G, Kalaitzidis D, Neel BG. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev 2008;2:179–92.
7. Chan RJ, Feng GS. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 2007;3:862–7.
8. Dong L, Yu WM, Zheng H, Loh ML, Bunting ST, Pauly M, et al. Leukaemo-genic effects of Ptpn11 activating mutations in the stem cell microenvironment. Nature 2016;539:304–8.
9. Zhou X, Coad J, Ducatman B, Agazie YM. SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis. Histopath 2008;53:389–402.
10. Aceto N, Sausgruber N, Brinkhaus H, Gaidatzis D, Martiny-Baron G, Mazzarol G, et al. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med 2012; 18:529–37.
11. Matalkah F, Martin E, Zhao H, Agazie YM. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer. Breast Cancer Res 2016;18:2.
12. Zhang K, Zhao H, Ji Z, Zhang C, Zhou P, Wang L, et al. Shp2 promotes metastasis of prostate cancer by attenuating the PAR3/PAR6/aPKC polarity protein complex and enhancing epithelial-to-mesenchymal transition. Oncogene 2016;35:1271–82.
13. Zhang RY, Yu ZH, Zeng L, Zhang S, Bai Y, Miao J, et al. SHP2 phosphatase as a novel therapeutic target for melanoma treatment. Oncotarget 2016; 7:73817–29.
14. Prahallad A, Heynen GJ, Germano G, Willems SM, Evers B, Vecchione L, et al. PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugs. Cell Rep 2015;12:1978–85.
15. Zeng LF, Zhang RY, Yu ZH, Li S, Wu L, Gunawan AM, et al. Therapeutic potential of targeting the oncogenic SHP2 phosphatase. J Med Chem 2014;57:6594–609.
16. Zhang X, He Y, Liu S, Yu Z, Jiang ZX, Yang Z, et al. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). J Med Chem 2010;53:2482–93.
17. Mali RS, Ma P, Zeng LF, Martin H, Ramdas B, He Y, et al. Role of SHP2 phosphatase in KIT induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT. Blood 2012;120: 2669–78.
18. Grosskopf S, Eckert C, Arkona C, Radetzki S, Bohm K, Heinemann U, et al. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo. Chem-MedChem 2015;10:815–26.
19. Chen YN, LaMarche MJ, Chan HM, Fekkes P, Garcia-Fortanet J, Acker MG, et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature 2016;535:148–52.
20. Bessette DC, Qiu D, Pallen CJ. PRL PTPs: mediators and markers of cancer progression. Cancer Metastasis Rev 2008;27:231–52.
21. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, et al. A phosphatase associated with metastasis of colorectal cancer. Science 2001;294:1343–6.
22. Bardelli A, Saha S, Sager JA, Romans KE, Markowitz SD, Lengauer C, et al. PRL-3 expression in metastatic cancers. Clin Cancer Res 2003;15:5607–15.
23. den Hollander P, Rawls K, Tsimelzon A, Shephard J, Mazumdar A, Fuqua SA, et al. Phosphatase PTP4A3 promotes triple-negative breast cancer growth and predicts poor patient survival. Cancer Res 2016;76:1942–53.
24. Gari HH, Gearheart CM, Fosmire S, DeGala GD, Fan Z, Torkko KC, et al. Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers. Oncotarget 2016;7:15757–71.
25. Wang L, Peng L, Dong B, Kong L, Meng L, Yan L, et al. Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome. Ann Oncol 2006;17:1517–22.
26. Kobayashi M, Bai Y, Chen S, Gao R, Yao C, Cai W, et al. Phosphatase PRL2 promotes oncogenic NOTCH1-Induced T-cell leukemia. Leukemia 2017;31:751–4.
27. Wang H, Quah SY, Dong JM, Manser E, Tang JP, Zeng Q. PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition. Cancer Res 2007;67:2922–6.
28. Hardy S, Uetani N, Wong N, Kostantin E, Labbe DP, Begin LR, et al. The protein tyrosine phosphatase PRL-2 interacts with the magnesium transporter CNNM3 to promote oncogenesis. Oncogene 2015;34: 986–95.
29. Funato Y, Yamazaki D, Mizukami S, Du L, Kikuchi K, Miki H. Membrane protein CNNM4-dependent Mg2þ efflux suppresses tumor progression. J Clin Invest 2014;124:5398–410.
30. Gulerez I, Funato Y, Wu H, Yang M, Kozlov G, Miki H, et al. Phospho-cysteine in the PRL-CNNM pathway mediates magnesium homeostasis. EMBO Rep 2016;17:1890–900.
31. Gimenez-Mascarell P, Oyenarte I, Hardy S, Breiderhoff T, Stuiver M, Kostantin E, et al. Structural basis of the oncogenic interaction of phosphatase PRL-1 with the magnesium transporter CNNM2. J Biol Chem 2017;292:786–801.
32. Zimmerman MW, Homanics GE, Lazo JS. Targeted deletion of the metastasis-associated phosphatase Ptp4a3 (PRL-3) suppresses murine colon cancer. PLoS One 2013;8:e58300.
33. Bai Y, Zhou HM, Zhang L, Dong Y, Zeng Q, Shou W, et al. Role of Phosphatase of Regenerating Liver 1 (PRL-1) in spermatogenesis. Sci Rep 2016;6:34211.
34. Dong Y, Zhang L, Zhang S, Bai Y, Chen H, Sun X, et al. Phosphatase of regenerating liver 2 (PRL2) is essential for placental development by down-regulating PTEN (Phosphatase and Tensin Homologue Deleted on Chromosome 10) and activating Akt protein. J Biol Chem 2012; 287:32172–9.
35. Dong Y, Zhang L, Bai Y, Zhou HM, Campbell AM, Chen H, et al. Phosphatase of regenerating liver 2 (PRL2) deficiency impairs Kit signaling and spermatogenesis. J Biol Chem 2014;289:3799–810.
36. Kobayashi M, Bai Y, Dong Y, Chen S, Gao R, Zhang L, et al. PRL2/PTP4A2 phosphatase is important for hematopoietic stem cell self-renewal. Stem Cells 2014;32:1956–7.
37. Hollander MC,Blumenthal GM,Dennis PA.PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011;11:289–301.
38. Daouti S, Li WH, Qian H, Huang KS, Holmgren J, Levin W, et al. A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage. Cancer Res 2008;68:1162–9.
39. Kostantin E, Hardy S, Valinsky WC, Kompatscher A, de Baaij JH, Zolotarov Y, et al. Inhibition of PRL-2CNNM3 protein complex formation decreases breast cancer proliferation and tumor growth. J Biol Chem 2016;291: 10716–25.
40. Salamoun JM, McQueeney KE, Patil K, Geib SJ, Sharlow ER, Lazo JS, et al. Photooxygenation of an amino-thienopyridone yields a more potent PTP4A3 inhibitor. Org Biomol Chem 2016;14:6398–402.
41. Hoeger B, Diether M, Ballester PJ, Kohn M. Biochemical evaluation of virtual screening methods reveals a cell-active inhibitor of the cancer-promoting phosphatases of regenerating liver. Eur J Med Chem 2014;88: 89–100.
42. Bai Y, Yu ZH, Liu S, Zhang L, Zhang RY, Zeng LF, et al. Novel anticancer agents based on targeting the trimer interface of the PRL phosphatase. Cancer Res 2016;76:4805–15.
43. Thura M, Al-Aidaroos AQ, Yong WP, Kono K, Gupta A, Lin YB, et al. PRL3-zumab, a first-in-class humanized antibody for cancer therapy. JCI Insight 2016;1:e87607.